Group 1 - The core viewpoint of the news highlights a strong performance in innovative drug concept stocks, with notable increases in companies such as WuXi AppTec and Kanglong Chemical, which rose over 7%, and others like Xinlitai, which increased over 3% [1] - The innovative drug-related ETFs also saw significant gains, with an overall increase of over 2% [1] Group 2 - Specific ETF performance includes the Innovative Drug Industry ETF rising by 2.59% to 0.633, and other ETFs like the Innovative Drug ETF and the EasyGo Innovative Drug ETF also showing increases of 2.45% and 2.40% respectively [2] - Analysts indicate that core assets in innovative drugs are expected to continue rising, with new opportunities emerging in areas such as small nucleic acids and in vivo CAR technologies [2] - The long-term trend of innovative drug business development (BD) is seen as a pathway for China's innovative drug capabilities to gain recognition on the global stage, with core assets licensed to multinational corporations (MNCs) expected to realize value as clinical progress continues [2]

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical industry [4] Core Insights - The pharmaceutical index rose by 7.81% from January 5 to January 9, outperforming the CSI 300 index by 5.03%. The brain-machine interface and AI medical sectors are expected to remain active in Q1 2026, with a strong rebound in innovative drugs, particularly small nucleic acids [5][25] - The report highlights the potential for significant advancements in small nucleic acids in 2026, driven by breakthroughs in liver-targeted delivery technologies and a surge in clinical data readouts [8][22] - The report emphasizes the importance of selecting innovative drug stocks with strong fundamentals and suggests focusing on companies that have undergone sufficient adjustments [5][49] Summary by Sections Industry Performance - The pharmaceutical index saw 443 stocks rise and 25 fall during the week, with notable gainers including Innovative Medical (+61.04%) and Sanbo Brain Science (+56.15%). Conversely, Baohua Pharmaceutical saw a decline of -21.65% [5][26][27] Small Nucleic Acids - 2026 is projected to be a pivotal year for the small nucleic acid sector, with advancements in liver-targeted delivery technologies and a high frequency of clinical data readouts expected [8][22] - Arrowhead's delivery platform has shown promising results in clinical trials, validating the feasibility of RNAi therapies for obesity and other conditions [9][11] Investment Recommendations - The report suggests focusing on companies with leading platform capabilities and differentiated pipeline layouts, such as Rebio Biotech, Yuyuan Pharmaceutical, and Frontier Biotech [20][24] - It also recommends a diversified investment approach, including innovative drugs, brain-machine interfaces, and AI medical technologies [47][48] Market Trends - The report notes that the aging population and increasing healthcare demands are driving growth in the pharmaceutical sector, with a focus on chronic diseases and innovative medical technologies [47] - The report highlights the ongoing trend of domestic companies enhancing their capabilities in the global market, particularly in innovative drug development and medical devices [46][47] Key Companies to Watch - Recommended stocks include China National Pharmaceutical Group, Rebio Biotech, Shanghai Yizhong, and Yuyuan Medical [49]

Core Viewpoint - The company, Xinlitai, announced that its self-developed innovative drug SAL0150 has received acceptance for clinical trial application by the National Medical Products Administration, targeting treatment for type 2 diabetes and its complications, as well as obesity or overweight, with a potential for once-a-week oral administration [1] Group 1 - The drug SAL0150 is an oral long-acting formulation [1] - The intended use of SAL0150 includes treatment for type 2 diabetes and its complications, as well as obesity or overweight [1] - The drug has the potential to be administered once a week, which may improve patient compliance [1]

Core Viewpoint - The company, Xinlitai (002294.SZ), has received an acceptance notice from the National Medical Products Administration for its clinical trial application of the innovative drug SAL0150, aimed at treating type 2 diabetes and its complications, as well as obesity or overweight conditions [1] Group 1 - The clinical trial application for SAL0150 has been officially accepted, marking a significant step in the drug's development process [1] - SAL0150 is being developed for multiple indications, including type 2 diabetes, its complications, and obesity or overweight [1]

Core Viewpoint - The company, Xinlitai (002294), has received approval from the National Medical Products Administration for its clinical trial application for the innovative drug SAL0150, aimed at treating type 2 diabetes and its complications, as well as obesity or overweight conditions [1]. Group 1 - The clinical trial application for SAL0150 has been officially accepted [1]. - SAL0150 is developed for the treatment of type 2 diabetes and its complications, along with obesity or overweight [1].

证券代码：002294 证券简称：信立泰 编号：2026-002 关于 SAL0150 药品临床试验申请获得受理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，深圳信立泰药业股份有限公司（下称"公司"）收到国家药品监督管 理局核准签发的受理通知书，公司自主研发的创新药 SAL0150 片（项目代码： SAL0150）临床试验申请获得受理。 现就相关信息公告如下： 一、药品基本情况 药品名称：SAL0150 片 申请事项：境内生产药品注册临床试验 深圳信立泰药业股份有限公司 自受理之日起 60 日内，未收到药审中心否定或质疑意见的，申请人可以按 照提交的方案开展临床试验。 公司本次提交的申请为 SAL0150 用于 2 型糖尿病及其并发症、肥胖或超重 的临床试验申请。 二、其他相关情况 SAL0150 是具有自主知识产权的口服长效药物，预计可以实现≥一周一次 的口服给药频次，对于肥胖、2 型糖尿病及其并发症等具有良好的治疗效果，安 全性较优，若能研发成功并获批上市，将有望为患者提供新的用药选择，满足未 被满足的临床需求，并进一步丰富公司慢病领域的创 ...

Core Viewpoint - The company, Sinopharm (002294.SZ), has received a notice of acceptance from the National Medical Products Administration for its clinical trial application of the innovative drug SAL0150, aimed at treating type 2 diabetes and its complications, as well as obesity or overweight conditions [1] Group 1 - The clinical trial application for SAL0150 has been officially accepted [1] - SAL0150 is developed independently by the company [1] - The application targets type 2 diabetes and its complications, along with obesity or overweight [1]

Core Viewpoint - The company has received acceptance from the National Medical Products Administration for the clinical trial application of its innovative drug SAL0150, aimed at treating type 2 diabetes and its complications, as well as obesity or overweight conditions [1] Group 1: Drug Development - SAL0150 is an oral long-acting medication with independent intellectual property rights, expected to allow for administration once a week or longer [1] - If successfully developed and approved for market, SAL0150 could enhance the company's pipeline of innovative products in the chronic disease sector [1] Group 2: Market Impact - The drug development cycle is lengthy and carries high risks, with uncertainties from clinical trials to market approval [1] - There is no immediate impact on the company's performance in the short term due to the nature of drug development [1]

Core Viewpoint - The company, Xinlitai, has received approval from the National Medical Products Administration for its clinical trial application of the innovative drug SAL0150, which is intended for the treatment of type 2 diabetes and its complications, as well as obesity or overweight conditions [1] Group 1: Drug Development - SAL0150 is an innovative drug developed by the company that possesses independent intellectual property rights [1] - The drug is expected to allow for an oral administration frequency of once a week or more [1] - Following the acceptance of the clinical application, the drug must still obtain implied permission for clinical trials and must adhere to national drug registration regulations to conduct these trials [1] Group 2: Market Impact - The clinical trial's success is necessary for the drug to be registered and submitted for approval [1] - The drug development cycle is lengthy and carries high risks, with various factors influencing the timeline from clinical trials to market launch [1] - There is uncertainty regarding the short-term impact on the company's performance due to the drug's development stage [1]

Group 1 - The A-share market continues to show strength in innovative drug concept stocks, with notable gains from companies such as Bibot-U nearing the daily limit and reaching a new high, and Yuandong Bio rising over 9% [1] - The National Medical Products Administration (NMPA) is set to support the "China debut" of innovative drugs, with plans to implement a data protection system for drug trials and establish exclusive market periods for pediatric and rare disease medications by 2026 [1] - The NMPA has announced further optimization of the review and approval process for urgently needed foreign drugs already on the market to meet the pressing clinical needs of patients [1] Group 2 - Notable stock performances include Bibot-U with a 19.95% increase, Yuandong Bio up 9.33%, and Hongbo Pharmaceutical rising 8.16%, among others [2] - The total market capitalization for Bibot-U is 22.3 billion, while Yuandong Bio stands at 11.5 billion, and Hongbo Pharmaceutical at 4.867 billion [2] - Year-to-date performance shows Bibot-U leading with a 70.89% increase, followed by Hongbo Pharmaceutical at 16.74% and Lai Mei Pharmaceutical at 7.59% [2]